Eisai to Present Data on Lecanemab and Other Alzheimer's Disease Research at the AD/PDz 2024 Annual Meeting

Eisai announced it will present the latest research on lecanemab, its anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer's disease (AD), at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PDz) from March 5-9 in Lisbon, Portugal, and virtually.

The lecanemab data and additional research findings from Eisai's AD portfolio will be featured in 18 presentations, including ten oral presentations. Eisai will present five oral presentations and one poster presentation on lecanemab results. From the Phase 3 Clarity AD study in subjects with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia (collectively known as early AD) with confirmed brain Aβ accumulation, presentations will include data on the effect of lecanemab treatment on tau accumulation in whole brain regions, and outcomes of long-term efficacy of lecanemab. In addition, the differences in the binding properties of multiple anti-amyloid (Aβ) antibodies to various types of Aβ and other data will be presented.

Eisai will also host a symposium titled "Defining meaningful benefits to patients, caregivers, and healthcare systems in Alzheimer's disease".

Lecoanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).